natgillin/translations-raw huggingface dataset:
The PET results were compared with the maximal neuritic plaque density measured on sections of middle frontal gyrus, superior and middle temporal gyri, inferior parietal lobe, hippocampus and other brain regions at the patient’s autopsy.
Rezultate PET-preiskave so primerjali z maksimalno gostoto nevritičnih leh, izmerjeno na predelih srednje frontalne vijuge, superiorne in srednje temporalne vijuge, inferiornega parietalnega režnja, hipokampusa in drugih možganskih predelih med obdukcijo bolnika.
The PET results were compared with the neuritic plaque density measured on sections of eight predefined brain regions at the patient’s autopsy.
Rezultati PET so bili primerjani z gostoto nevritičnih leh, izmerjeno v odsekih osmih vnaprej definiranih območjih možganov pri obdukciji bolnikov.
The PFS benefit of Kd was consistently observed in all subgroups, including patients ≥ 75 years of age (n = 143), patients with high risk (n = 210) genetic mutations, and patients with baseline creatinine clearance of 30 - < 50mL/min (n = 128).
Korist Kd za PFS je bila dosledno opazna v vseh podskupinah, vključno z bolniki, starimi ≥ 75 let (n = 143), bolniki z genetskimi mutacijami z velikim tveganjem (n = 210) in bolniki z izhodiščnim očistkom kreatinina 30 - < 50 ml/min (n = 128).
The PFS benefit of KRd was consistently observed in all subgroups, including patients ≥ 75 years of age (n = 96), patients with high risk (n = 100) or unknown (n = 375) risk genetic mutations, and patients with baseline creatinine clearance of 30 - < 50mL/min (n = 56).
Koristni vpliv KRd na PFS je bil dosledno opažen v vseh podskupinah, vključno z bolniki, starimi ≥ 75 let (n = 96), bolniki z velikim tveganjem (n = 100) ali mutacijami genov z neznanim tveganjem (n = 375) ter pri bolnikih z izhodiščnim očistkom kreatinina od 30 do < 50 ml/min (n = 56).
The PFS HRs (pooled pembrolizumab [10 mg/kg every 2 or 3 weeks] vs. ipilimumab) were 0.57 (95% CI: 0.45, 0.73) for BRAF wild type, 0.50 (95% CI: 0.32, 0.77) for BRAF mutant without prior BRAF treatment, and 0.73 (95% CI: 0.48, 1.11) for BRAF mutant with prior BRAF treatment.
RO za preživetje brez napredovanja bolezni (kumulativno pembrolizumab [10 mg/kg na 2 ali 3 tedne] v primerjavi z ipilimumabom) so bila 0,57 (95 % IZ: 0,45; 0,73) za divji tip BRAF, 0,50 (95 % IZ: 0,32; 0,77) za mutacijo BRAF brez predhodnega zdravljenja BRAF in 0,73 (95 % IZ: 0,48; 1,11) za mutacijo BRAF s predhodnim zdravljenjem BRAF.
The PFS HRs (pooled pembrolizumab [2 mg/kg or 10 mg/kg every 3 weeks] vs. chemotherapy) were 0.51 (95% CI: 0.41, 0.65) for BRAF wild type and 0.56 (95% CI: 0.37, 0.85) for BRAF mutant with prior BRAF treatment.
Razmerji ogroženosti (RO) za preživetje brez napredovanja bolezni (kumulativno pembrolizumab [2 mg/kg ali 10 mg/kg na 3 tedne] v primerjavi s kemoterapijo) sta bili 0,51 (95 % IZ: 0,41; 0,65) za divji tip BRAF in 0,56 (95 % IZ: 0,37; 0,85) za mutacijo BRAF s predhodnim zdravljenjem BRAF.
The PFS HRs for pembrolizumab 2 mg/kg every 3 weeks vs. chemotherapy were 0.54 (95% CI: 0.39, 0.75) for PD-L1 positive patients and 0.89 (95% CI: 0.53, 1.50) for PD-L1 negative patients.
RO za preživetje brez napredovanja bolezni za pembrolizumab 2 mg/kg na 3 tedne v primerjavi s kemoterapijo sta bili med PD-L1 pozitivnimi bolniki 0,54 (95 % IZ: 0,39; 0,75), med PD-L1 negativnimi pa 0,89 (95 % IZ: 0,53; 1,50).
The PFS in the monotherapy Arzerra arm was comparable to the results seen with Arzerra monotherapy in study Hx-CD20-406.
Preživetje brez napredovanja je bilo v skupini, ki je prejemala monoterapijo z zdravilom Arzerra, podobno kot med monoterapijo z zdravilom Arzerra v študiji
The PFS result was consistent in the subgroup of patients with V600K mutation positive melanoma (HR = 0.50; [95% CI: 0.18, 1.35], p=0.0788).
Rezultat PFS se je skladal v podskupini bolnikov, ki so imeli melanom s pozitivno mutacijo V600K (razmerje ogroženosti = 0,50, [95 % IZ: 0,18, 1,35], p = 0,0788).
The pH of the reconstituted solution is 4.0-6.0.
pH rekonstituirane raztopine je 4,0 do 6,0.
The pH of the reconstituted solution is 5.9 – 6.5.
pH rekonstituirane raztopine je 5,9 do 6,5.
The pH of the reconstituted solution is 7.5-8.5.
pH rekonstituirane raztopine je 7,5–8,5.
The pH of the reconstituted solution is approximately 7.0. Before further dilution, visually inspect the reconstituted solution in each vial for particulate matter and discoloration.
Pred nadaljnjim redčenjem vizualno preglejte rekonstituirano raztopino v vsaki viali, da ugotovite delce in obarvanje.
The pH of the reconstituted solution is between 6.6 and 7.8. Further dilution is required.
Raztopino je treba še dodatno razredčiti.
The pH of the reconstituted solution is between 6.6 and 7.8. Further dilution is required.
Raztopino moramo še dodatno razredčiti.
The pH of the reconstituted solution is between 6.6 and 7.8. Further dilution is required.
Raztopino moramo še nadalje redčiti.
The pH of the reconstituted solution is between 6.6 and 7.8. Further dilution is required.
Raztopino se mora še nadalje redčiti.
The pharmacist educational material should contain:
Izobraževalno gradivo za farmacevte mora vsebovati:
The pharmacist may compound a 6 mg/ml suspension from Ebilfumin 30 mg, 45 mg or 75 mg capsules using water containing 0.05 % w/v sodium benzoate added as a preservative.
Farmacevt lahko pripravi 6 mg/ml suspenzijo iz 30 mg, 45 mg ali 75 mg kapsul zdravila Ebilfumin in vode, ki vsebuje 0,05 % m/v natrijevega benzoata kot konzervans.
The pharmacist may compound a 6 mg/ml suspension from Tamiflu 30 mg, 45 mg or 75 mg capsules using water containing 0.05 % w/v sodium benzoate added as a preservative.
Farmacevt lahko pripravi 6 mg/ml suspenzijo iz 30 mg, 45 mg ali 75 mg kapsul Tamiflu in vode, ki vsebuje 0,05 % m/v natrijevega benzoata kot konzervans.
The pharmacist may compound a 6 mg/ml suspension from Tamiflu 30 mg, 45 mg or 75 mg capsules using water containing 0.05 % w/v sodium benzoate added as a preservative.
Farmacevt lahko pripravi 6 mg/ml suspenzijo iz 30-mg, 45-mg ali 75-mg kapsul Tamiflu in vode, ki vsebuje 0,05 % m/v natrijevega benzoata kot konzervans.
The pharmacist must be familiar with the educational material of Instanyl nasal spray before using it in his/her organisation.
Farmacevt mora biti pred uporabo zdravila v svoji ustanovi seznanjen z izobraževalnimi gradivi o Instanyl pršilu za nos.
The pharmacist must inform the patients that in order to prevent theft and misuse of Instanyl nasal spray they have to keep it in a safe place to avoid misuse and diversion.
Farmacevt mora obvestiti bolnika, da je treba Instanyl pršilo za nos zaradi preprečevanja kraje in zlorabe shranjevati na varnem mestu, kjer ni možna zloraba ali napačna uporaba.
The pharmacist must make use of the checklist for pharmacist
Farmacevt mora uporabiti kontrolni seznam za farmacevte.
The pharmacist or nurse will calculate the exact dose you need.
Farmacevt ali medicinska sestra bosta izračunala natančni odmerek, ki ga potrebujete.
The pharmacist will write the date of expiration on the bottle label in the black box next to "Use before".
Farmacevt bo rok uporabnosti suspenzije napisal na nalepko stekleničke v črno polje poleg zapisa »Uporabno do«.
The pharmacodynamic effect of alirocumab in lowering LDL-C is indirect, and mediated through the binding to PCSK9.
Farmakodinamični vpliv alirokumaba na znižanje LDL-H je posreden in poteka preko vezave na PCSK9.
The pharmacodynamic effect of factor VIIa gives rise to an increased local formation of factor Xa, thrombin and fibrin.
Farmakodinamični učinek faktorja VIIa povzroči zvečano lokalno nastajanje faktorja Xa, trombina in fibrina.
The pharmacodynamic effect of Ryzodeg is distinctively separated for the two components (Figure 1) and the resulting action profile reflects the individual components, the rapid-acting insulin aspart and the basal component insulin degludec.
Farmakodinamični učinek zdravila Ryzodeg je za obe sestavini jasno ločen (slika 1); njegov profil delovanja odraža obe sestavini, hitrodelujoči insulin aspart in bazalno sestavino insulin degludek.
The pharmacodynamic effect of warfarin on International Normalized Ratio (INR) was not affected by macitentan.
Macitentan ni vplival na farmakodinamični učinek varfarina na mednarodno normalizirano razmerje (INR, International Normalized Ratio).
The pharmacodynamic effects of Aerinaze tablets are directly related to that of its components.
Farmakodinamični učinki zdravila Aerinaze tablete so neposredno povezani s farmakodinamiko njegovih sestavin.
The pharmacodynamic properties of 64Cu-labelled medicinal products prepared by radiolabelling with Cuprymina, prior to administration, will be dependent on the nature of the medicinal product to be radiolabelled.
Farmakodinamične lastnosti z bakrom (64Cu) označenih zdravil, pripravljenih z radioaktivnim označevanjem z radiofarmacevtskim predhodnikom Cuprymina pred dajanjem, bodo odvisne od vrste zdravila, ki bo radioaktivno označeno.
The pharmacodynamic properties of Yttrium (90Y)-labelled medicinal products prepared by radiolabelling with YTRACIS, prior to administration, will be dependent on the nature of the medicinal product to be radiolabelled.
Farmakodinamične lastnosti z itrijem (90Y) označenih zdravil, ki so pripravljena z uporabo YTRACISa pred aplikacijo, so odvisne od vrste zdravila, ki naj bi ga označili z radioaktivnim izotopom.
The pharmacodynamically predictable and most commonly reported adverse reactions are thirst, dry mouth and pollakiuria occurring in approximately 18%, 9% and 6% of patients.
Farmakodinamično predvidljivi in najbolj pogosto poročani neželeni učinki so bili žeja, suha usta in polakiurija, ki se pojavijo pri približno 18 %, 9 % in 6 % bolnikov.
The pharmacodynamics of 5 mg dapagliflozin twice daily and 10 mg dapagliflozin once daily were compared in healthy subjects.
Farmakodinamiko 5 mg dapagliflozina dvakrat na dan in 10 mg dapagliflozina enkrat na dan so primerjali pri zdravih preiskovancih.
The pharmacokinetic (PK) parameters in the anti-TNF inadequate responder population, following the same dosage regimen (2 x 1000 mg, IV, 2 weeks apart), were similar with a mean maximum serum concentration of 369 g/mL and a mean terminal half-life of 19.2 days.
Farmakokinetični parametri pri bolnikih, ki niso zadovoljivo odgovorili na zdravljenje z zaviralci TNF, po enakem odmerjanju (2 x 1.000 mg, intravensko, v razmiku 2 tednov) so bili podobni s povprečno maksimalno koncentracijo v serumu 369 µg/ml in povprečnim končnim razpolovnim časom 19,2 dneva.
The Pharmacokinetic (PK) profile of Kovaltry was evaluated in PTPs with severe haemophilia A following 50 IU/kg in 21 subjects ≥ 18 years, 5 subjects ≥ 12 years and < 18 years and 19 subjects
Farmakokinetični (FK) profil zdravila Kovaltry so ocenili pri predhodno zdravljenih bolnikih s hudo hemofilijo A po prejemu 50 i.e./kg pri 21 osebah ≥ 18 let, 5 osebah ≥ 12 let in < 18 let in 19 osebah
The pharmacokinetic /pharmacodynamic (PK/PD) relationship between apixaban plasma concentration and several PD endpoints (anti-FXa activity, INR, PT, aPTT) has been evaluated after administration of a wide range of doses (0.5 – 50 mg).
Razmerje med farmakokinetiko/farmakodinamiko (PK/PD) med plazemskimi koncentracijami apiksabana in različnimi farmakodinamičnimi opazovanimi dogodki (aktivnost anti-FXa, INR, PČ, PTČ) so ovrednotili pri širokem razponu uporabljenih odmerkov (0,5 do 50 mg).
The pharmacokinetic absorption profile will repeat with each application to a new skin site, therefore with each new application, absorption will be lower initially.
Farmakokinetični absorpcijski profil se ponovi pri vsaki aplikaciji na nov kožni predel, zato je pri vsaki novi aplikaciji absorpcija na začetku manjša.
The pharmacokinetic and pharmacodynamic findings indicate that the effect of the subcutaneous injection with insulin glargine is principally based on exposure to M1.
Farmakokinetični in farmakodinamski izsledki kažejo, da učinek subkutano injiciranega insulina glargin temelji predvsem na izpostavljenosti presnovku M1.
The pharmacokinetic and pharmacodynamic findings indicate that the effect of the subcutaneous injection with insulin glargine is principally based on exposure to M1.
Farmakokinetični in farmakodinamski izsledki kažejo, da učinek subkutano injiciranega insulina glargina temelji predvsem na izpostavljenosti presnovku M1.
The pharmacokinetic and pharmacodynamic findings indicate that the effect of the subcutaneous injection with Lantus is principally based on exposure to M1.
Farmakokinetični in farmakodinamski izsledki kažejo, da učinek subkutano injiciranega zdravila Lantus temelji predvsem na izpostavljenosti presnovku M1.
The pharmacokinetic and pharmacodynamic findings indicate that the effect of the subcutaneous injection with Toujeo is principally based on exposure to M1.
Farmakokinetični in farmakodinamski izsledki kažejo, da učinek subkutano injiciranega zdravila Toujeo temelji predvsem na izpostavljenosti presnovku M1.
The pharmacokinetic and pharmacodynamic properties of insulin glulisine were investigated in children (7-11 years) and adolescents (12-16 years) with type 1 diabetes mellitus.
Farmakokinetične in farmakodinamične lastnosti insulina glulisin so raziskali pri otrocih (7–11 let) in mladostnikih (12–16 let) z diabetesom mellitusom tipa 1.
The pharmacokinetic and pharmacodynamic properties of NovoRapid were investigated in children (6–12 years) and adolescents (13–17 years) with type 1 diabetes.
Farmakokinetične in farmakodinamične lastnosti zdravila NovoRapid so raziskali pri otrocih (6– 12 let) in mladostnikih (13–17 let) s sladkorno boleznijo tipa 1.
The pharmacokinetic data from HIV-1 infected pregnant women receiving lopinavir/ritonavir tablets 400/100 mg twice daily are presented in Table 6 (see section 4.2).
Farmakokinetični podatki pri nosečnicah, okuženih s HIV-1, ki so prejemale lopinavir/ritonavir tablete 400/100 mg tablete dvakrat dnevno, so prikazani v Preglednici 6 (glejte poglavje 4.2).
The pharmacokinetic enhancing effect of cobicistat on darunavir was evaluated in a phase 1 clinical study GS-US-216-0115 in 31 healthy subjects that were administered darunavir 800 mg in combination with cobicistat 150 mg or ritonavir 100 mg, all once daily, for 10 days.
Učinek farmakokinetične okrepitve, ki ga ima kobicistat na darunavir, so ovrednotili v klinični študiji faze 1 GS-US-216-0115 pri 31 zdravih osebah, ki so 10 dni dobivale darunavir 800 mg v kombinaciji s kobicistatom 150 mg ali ritonavirjem 100 mg, oboje enkrat na dan.
The pharmacokinetic enhancing effect of cobicistat on darunavir was evaluated in a Phase I study in healthy subjects that were administered darunavir 800 mg with either cobicistat at 150 mg or ritonavir at 100 mg once daily.
Učinek farmakokinetičnega ojačevalca kobicistata na darunavir so ocenili v študiji faze I pri zdravih prostovoljcih, ki so prejemali 800 mg darunavirja skupaj s 150 mg kobicistata ali s 100 mg ritonavirja enkrat na dan.
The pharmacokinetic interactions between rufinamide and other antiepileptic medicinal products have been evaluated in patients with epilepsy using population pharmacokinetic modelling.
Farmakokinetične interakcije med rufinamidom in drugimi antiepileptičnimi zdravili so ocenjevali pri bolnikih z epilepsijo s populacijskim modeliranjem farmakokinetike.
The pharmacokinetic parameters from the chromogenic assay data were similar to those derived for the one- stage assay.
Farmakokinetični parametri iz podatkov kromogenega preskusa so bili podobni tistim, izpeljanim iz enostopenjskega strjevalnega preskusa.
The pharmacokinetic parameters of Caelyx (primarily representing pegylated liposomal doxorubicin hydrochloride and low levels of unencapsulated doxorubicin hydrochloride) observed after the 20 mg/m2 doses are presented in Table 10.
Farmakokinetični parametri zdravila Caelyx (v prvi vrsti za pegiliran liposomski doksorubicinijev klorid in majhno koncentracijo neinkapsuliranega doksorubicinijevega klorida), ugotovljeni po odmerku 20 mg/m2, so prikazani v preglednici 10.
The pharmacokinetic parameters of eltrombopag in paediatric subjects with ITP are shown in Table 10.
Farmakokinetični parametri eltrombopaga pri pediatričnih bolnikih z ITP so prikazani v preglednici 10.
The pharmacokinetic parameters of regadenoson have not yet been studied in the paediatric population (< 18 years).
Farmakokinetičnih parametrov regadenozna do sedaj niso preučili pri pediatrični populaciji (< 18 let).
The pharmacokinetic parameters of tocilizumab did not change with time.
Farmakokinetični parametri tocilizumaba se s časom niso spreminjali.
The pharmacokinetic parameters of total irinotecan and SN-38 analytes, following the administration of ONIVYDE 80 mg/m2 are presented in Table 5.
Farmakokinetični parametri analitov skupnega irinotekana in SN-38 po dajanju zdravila ONIVYDE 80 mg/m2 so predstavljeni v preglednici 5.
The pharmacokinetic parameters quoted below are based on population parameter estimates for the 563 patients who received Benlysta 10 mg/kg in the two Phase III studies.
Spodaj navedeni farmakokinetični parametri temeljijo na populacijski oceni parametrov pri 563 bolnikih, ki so prejemali 10 mg/kg zdravila Benlysta v dveh študijah III. faze.
The pharmacokinetic profile has been studied in a small number (n=18) of diabetic children (aged 6- 12 years) and adolescents (aged 13-17 years) using another fast-acting human insulin, (Actrapid).
Farmakokineticni profil zdravila Velosulin je bil raziskan pri majhnem številu (n = 18) diabeticnih otrok (starost 6–12 let) in mladostnikov (starost 13–17 let)., ki so uporabljali drug hitro delujoc insulin (Actrapid).
The pharmacokinetic profile of a 20 mg dose of tasimelteon was compared among 8 subjects with mild hepatic impairment (Child-Pugh Score ≥5 and ≤6 points), 8 subjects with moderate hepatic impairment (Child-Pugh Score ≥7 and ≤9 points), and 13 healthy matched controls.
Farmakokinetični profil 20-miligramskega odmerka tasimelteona so primerjali pri osmih osebah z blago okvaro jeter (≥ 5 in ≤ 6 točk na Child-Pughovi lestvici), osmih osebah z zmerno okvaro jeter (≥ 7 in ≤ 9 točk na Child-Pughovi lestvici) ter 13 primerljivih zdravih kontrolnih osebah.
The pharmacokinetic profile of a 20 mg dose of tasimelteon was compared among 8 subjects with severe renal impairment (estimated glomerular filtration rate [eGFR] ≤ 29 mL/min/1.73m2), 8 subjects with end- stage renal disease (ESRD) (GFR < 15 mL/min/1.73m2) requiring hemodialysis, and 16 healthy matched controls.
Farmakokinetični profil 20-miligramskega odmerka tasimelteona so primerjali pri osmih osebah s hudo okvaro ledvic (ocenjena hitrost glomerulne filtracije [eGFR] ≤ 29 ml/min/1,73 m2), osmih osebah z boleznijo ledvic v zadnjem stadiju (hitrost glomerulne filtracije < 15 ml/min/1,73 m2), ki so potrebovale hemodializo, in 16 primerljivih zdravih kontrolnih osebah.
The pharmacokinetic profile of Actrapid has been studied in a small number (n=18) of diabetic children (aged 6–12 years) and adolescents (aged 13–17 years).
Farmakokinetični profil zdravila Actrapid je bil raziskan pri majhnem številu (n = 18) otrok (starost 6– 12 let) in mladostnikov (starost 13–17 let) s sladkorno boleznijo.
The pharmacokinetic profile of cisplatin administered shortly after docetaxel infusion is similar to that observed with cisplatin alone.
Farmakokinetični profil cisplatina, uporabljenega kmalu po infuziji zdraviladocetaksel, je podoben kot po uporabi samega cisplatina.
The pharmacokinetic profile of lutropin alfa is similar to that of urinary- derived hLH.
Farmakokinetični profil lutropina alfa je podoben profilu hLH urinskega izvora.
The pharmacokinetic profile of teduglutide in this paediatric population, as evaluated by clearance and volume of distribution, was different from that observed in adults after correcting for body weights.
Farmakokinetični profil teduglutida v tej pediatrični populaciji, ocenjen z očistkom in volumnom porazdelitve, se je razlikoval od tistega, ki so ga ugotovili pri odraslih po popravku za telesne mase.
The pharmacokinetic profiles of maltol/maltol glucuronide and iron parameters were independent of one another.
Farmakokinetična profila maltola/maltolovega glukuronida in parametri železa so bili med seboj neodvisni.
The pharmacokinetic profiles of transdermal and oral combined hormonal contraceptives are different and caution should be exercised when making a direct comparison of these PK parameters.
Farmakokinetični profili transdermalnih in peroralnih kombiniranih hormonskih kontraceptivov se med seboj razlikujejo, zato je potrebna previdnost pri neposredni primerjavi farmakokinetičnih parametrov.
The pharmacokinetic properties are not dose or time dependent in the range of eribulin doses of 0.22 to 3.53 mg/m2.
Farmakokinetične lastnosti eribulina v razponu odmerka 0,22 do 3,53 mg/m2 niso odvisne od odmerka ali časa.
The pharmacokinetic properties described below have to a large extent been derived from a population pharmacokinetic analysis with data from 1507 patients with various types of advanced malignancies.
Spodaj opisane farmakokinetične lastnosti v veliki meri izvirajo iz populacijske farmakokinetične analize podatkov 1507 bolnikov z različnimi vrstami napredovalih malignomov.
The pharmacokinetic properties have not been investigated in patients with impaired liver function.
Farmakokinetične lastnosti pri bolnikih z okvarjenim delovanjem jeter niso raziskane.
The pharmacokinetic properties of 64Cu-labelled medicinal products prepared by radiolabelling with Cuprymina, prior to administration, will be dependent on the nature of the medicinal product to be radiolabelled.
Farmakokinetične lastnosti z bakrom (64Cu) označenih zdravil, pripravljenih z radioaktivnim označevanjem z radiofarmacevtskim predhodnikom Cuprymina pred dajanjem, bodo odvisne od vrste zdravila, ki bo radioaktivno označeno.
The pharmacokinetic properties of aclidinium bromide in patients with moderate to severe COPD appear to be similar in patients aged 40–59 years and in patients aged ≥70 years.
Farmakokinetične lastnosti aklidinijevega bromida pri bolnikih z zmerno do hudo boleznijo KOPB so podobne pri bolnikih v starostni skupini od 40 do 59 let in pri bolnikih, starih ≥70 let.
The pharmacokinetic properties of entacapone are similar in both young and elderly adults.
Farmakokinetične lastnosti entakapona so podobne tako pri mlajših kot pri starejših odraslih osebah.
The pharmacokinetic properties of lamivudine have been determined in a small group of HIV-1-infected adults with impaired renal function.
Farmakokinetične lastnosti lamivudina so proučili v majhni skupini odraslih, okuženih s HIV-1, z okvarjenim delovanjem ledvic.
The pharmacokinetic properties of Levemir were investigated in young children (1–5 years), children (6–12 years) and adolescents (13–17 years) and compared to adults with type 1 diabetes.
Farmakokinetične lastnosti zdravila Levemir so raziskali pri mlajših otrocih (od 1. do 5. leta), otrocih (od 6. do 12. leta) in mladostnikih (od 13. do 17. leta) in jih primerjali s tistimi pri odraslih s sladkorno boleznijo tipa 1.
The pharmacokinetic properties of Levemir were investigated in young children (1–5 years), children(6–12 years) and adolescents (13–17 years) and compared to adults with type 1 diabetes.
Farmakokinetične lastnosti zdravila Levemir so raziskali pri mlajših otrocih (od 1. do 5. leta), otrocih (od 6. do 12. leta) in mladostnikih (od 13. do 17. leta) in jih primerjali s tistimi pri odraslih s sladkorno boleznijo tipa 1.
The pharmacokinetic properties of Lutetium (177Lu)-labelled medicinal products prepared by radiolabelling with Lumark, prior to administration, will be dependent on the nature of the medicinal product to be radiolabelled.
Farmakokinetične lastnosti z lutecijem (177Lu) označenih zdravil, pripravljenih z radioaktivnim označevanjem z radionuklidnim predhodnikom Lumark pred dajanjem, bodo odvisne od vrste zdravila, ki bo radioaktivno označevano.
The pharmacokinetic properties of nintedanib were similar in healthy volunteers, cancer patients, and patients of the target population.
Farmakokinetične lastnosti nintedaniba so bile pri zdravih prostovoljcih podobne kot pri bolnikih z rakom in bolnikih v ciljni populaciji.